3000 Participants Needed

Genetic Study for Coronary Artery Dissection

AS
JA
Overseen ByJohandra Argote Parolis, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Cardiology Research UBC
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on understanding the long-term effects of Spontaneous Coronary Artery Dissection (SCAD). Researchers observe patients who have experienced an acute coronary syndrome, such as a heart attack or severe chest pain, and have confirmed SCAD through specific heart imaging tests. The trial includes a genetic sub-study to determine if hereditary factors play a role. It suits those hospitalized for SCAD without significant blockage from coronary artery disease. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that may enhance future SCAD treatments.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

Why are researchers excited about this trial?

Researchers are excited about this genetic sub-study for SCAD (Spontaneous Coronary Artery Dissection) because it aims to uncover genetic factors that might predispose individuals to this condition. Unlike standard treatments that focus on managing symptoms or repairing arteries, this study dives into the genetic makeup, which could lead to personalized medicine approaches. By identifying specific genetic markers, there is potential to predict risk better and tailor prevention strategies, which is a significant leap forward in managing SCAD compared to current treatment methods.

Who Is on the Research Team?

JS

Jacqueline Saw, MD

Principal Investigator

Cardiology Research UBC / Vancouver General Hospital

Are You a Good Fit for This Trial?

Inclusion Criteria

Documented SCAD on a coronary angiogram (including diagnosis with OCT or IVUS)
Patients admitted with ACS (STEMI, NSTEMI or unstable angina)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Detailed baseline demographics, targeted history for precipitating stressors and predisposing conditions, and investigations for predisposing conditions

During index hospitalization

In-hospital Observation

Monitoring of in-hospital CV outcomes including death, MI, CVA, unplanned revascularization, and heart failure

Up to 8 weeks

Short-term Follow-up

Assessment of arterial healing post SCAD via angiographic healing

6 weeks post discharge

Long-term Follow-up

Participants are monitored for long-term CV outcomes including death, MI, CVA, revascularization, and heart failure

10 years

What Are the Treatments Tested in This Trial?

Interventions

  • Genetic sub-study

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Study groupExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cardiology Research UBC

Lead Sponsor

Trials
16
Recruited
7,100+

John GB Mancini, MD

Collaborator

Trials
1
Recruited
3,000+

Karin Humphries, DSc

Collaborator

Trials
1
Recruited
3,000+